Ticagrelor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ticagrelor Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
610
Registered trials
315
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ticagrelor can convert its Small molecule drug profile and P2Y12 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ticagrelor (query alias: Ticagrelor) |
|---|---|
| Modality / target | Small molecule drug; P2Y12 receptor; P2Y12 receptor antagonists |
| Highest global status | Approved |
| Originator | AstraZeneca Pharmaceuticals Co. Ltd. |
| Active developers | AstraZeneca KK, AstraZeneca Pty Ltd., AstraZeneca AB |
The MCP disease footprint includes Acute Ischemic Stroke, Ischemic Attack, Transient, Coronary Artery Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07622056 | Phase 4 | Completed | 60 | Change in P2Y12 reaction units (PRU) from baseline to follow-up (VerifyNow P2Y12 assay) |
| NCT07610577 | Not Applicable | Completed | 377753 | Population-level trends in age- and sex-standardized proportions of clopidogrel, ticagrelor, and prasugrel initiators over time |
| NCT07613840 | Not Applicable | Recruiting | 484 | Incidence of Arterial Thrombosis in the Treated Limb |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Risk factors of bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention: an analysis from the MANJUSRI study
Phase 4; n=721; evaluation: Negative. Reported fields: Overall bleeding(6-month) = 35.62 % ; Overall bleeding(6-month) = 36.49 %
A Randomized Controlled Trial of Patients Undergoing Percutaneous Coronary Intervention Who Receive Ticagrelor and Fentanyl
Phase 4; n=45; evaluation: not stated. Reported fields: Area Under the Platelet Function Testing (PFT)-Time Curve (AUC0-6) for the First 6 Hours After the Loading Dose of Ticagrelor(Median) = 796.34 Platelet Reactive Units (PRUs)/hour (Inter-Quartile Range, 420.23 - 950.36); -; Area Under the Platelet Function Testing (PFT)-Time Curve (AUC0-6) for the First 6 Hours After the Loading Dose of Ticagrelor(Median) = 622.37 Platelet Reactive Units (PRUs)/hour (Inter-Quartile Range, 439.28 - 712.04)
Optimal timing of aspirin discontinuation with ticagrelor monotherapy in acute coronary syndrome: a post hoc comparative analysis from the TICO and T-PASS trials
Phase 4; n=2248; evaluation: Positive. Reported fields: Ischaemic event = 2.3 % ; Ischaemic event = 2.2 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ticagrelor addresses Acute Ischemic Stroke, Ischemic Attack, Transient, Coronary Artery Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-03-18 | 科兴制药与常州制药厂达成两款心血管药物欧洲商业化合作 | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Ticagrelor and aspirin compound preparation and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Ticagrelor iv for use in the prevention of thromboembolic events”. The milestone feed surfaced a patent-application signal described as “Ticagrelor iv for use in the treatment, reduction or prevention of an ischemic event in a patient undergoing a percutaneous coronary intervention (PCI)”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
